Examining the “revisability” benefit of hip resurfacing arthroplasty

Table 5 Patient reported outcomes between all cause conversion total hip arthroplasty, metal-related pathologies, and non-metal-related pathologies revision compared to revision total hip arthroplasty

Ref.	Patient reported outcome	Revision THA	Conversion THA (P value)	Non-MRP (P value)	MRP (P value)
Lübbeke et al[18], 2012	HHS	76.7 ± 18.1	81.7 ± 13.8 (0.12)	85.2 ± 11.5 (0.04a)	77.1 ± 14.5 (0.93)
	SF-12 PCS	36.5 ± 8.6	51.0 ± 8.1 (< 0.01a)	55.2 ± 4.3 (< 0.01a)	45.6 ± 8.9 (< 0.01a)
	SF-12 MCS	46.5 ± 11.2	53.0 ± 10.8 (< 0.01a)	55.3 ± 8.7 (< 0.01a)	50.1 ± 12.6 (0.23)
Postler et al[20], 2017	UCLA	4.1 ± 1.6	7.5 ± 2.3 (< 0.01a)	8.5 ± 1.8 (< 0.01a)	6.1 ± 2.3 (< 0.01a)

^aP < 0.05.

MRP: Metal-related pathologies; THA: Total hip arthroplasty; mHHS: Modified Harris Hip Score; HHS: Harris Hip Score; UCLA: University of California Los Angeles activity level; SF-12 PCS: Short-Form 12 Physical Component Score; SF-12 MCS: Short-Form 12 Mental Component Score.